Werewolf Therapeutics, Inc.
No enriched coverage for $HOWL in the last 7 days.
No SEC Form 4 filings for $HOWL in the last 30 days.
FactSet says about 75% of S&P 500 firms beat EPS estimates, but only about 60% beat revenue expectations. LSEG research finds earnings forecasts get more accurate as results near, so large surprises are rarer. The article lists nine Q2 companies with notable EPS beats, including HOWL, ABR, PWP, CRI, NWL, MOG-A, MGA, LYB, and NVT, with EPS and beat amounts cited.
Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a06302026ex991.htm EX-99.1 Document Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates Watertown, Mass., July 31, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL),
RA CAPITAL MANAGEMENT, L.P. sold 416,911 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.35 ($0.15M total) across 2 trades on 2026-06-17.
Recent HOWL coverage spans insider activity and earnings.
EPS beat suggests near-term upside to estimates and sentiment, but magnitude is the key driver.
The Jazz program sale and K2 repayment are concrete balance-sheet and pipeline-structure changes, while the cash drop frames near-term runway and financing risk.
The filing discloses a sizable insider/affiliate sale with no 10b5-1 plan, which can pressure sentiment and raise near-term overhang risk.
A 10%-owner open-market sale disclosed on Form 4 can pressure sentiment and raise near-term overhang concerns, though it’s not necessarily bearish on fundamentals.
Insider selling by a large 10% owner can pressure sentiment and near-term order flow, especially at sub-$1 liquidity levels.
alphai scores every news story that mentions HOWL with an AI model for sentiment and relevance, and aggregates insider trades from Werewolf Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
FactSet says about 75% of S&P 500 firms beat EPS estimates, but only about 60% beat revenue expectations. LSEG research finds earnings forecasts get more accurate as results near, so large surprises are rarer. The article lists nine Q2 companies with notable EPS beats, including HOWL, ABR, PWP, CRI, NWL, MOG-A, MGA, LYB, and NVT, with EPS and beat amounts cited.
7 min readWerewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a06302026ex991.htm EX-99.1 Document Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates Watertown, Mass., July 31, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL),
4 min readRA CAPITAL MANAGEMENT, L.P. sold 416,911 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.35 ($0.15M total) across 2 trades on 2026-06-17.
2 min readRA CAPITAL MANAGEMENT, L.P. sold 448,836 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.39 ($0.37–$0.40, $0.17M total) across 6 trades over 2026-06-12 to 2026-06-16.
2 min readRA CAPITAL MANAGEMENT, L.P. sold 678,226 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.37 ($0.37–$0.38, $0.25M total) across 6 trades over 2026-06-09 to 2026-06-11.
1 min readEVNIN LUKE sold 29,749 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.42 on 2026-06-03 under a Rule 10b5-1 trading plan.
2 min readEVNIN LUKE sold 29,595 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.45 on 2026-06-02 under a Rule 10b5-1 trading plan.
3 min readEVNIN LUKE sold 80,459 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.47 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readEVNIN LUKE sold 32,556 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.45 on 2026-05-29 under a Rule 10b5-1 trading plan.
2 min readEVNIN LUKE sold 27,698 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.46 on 2026-05-28 under a Rule 10b5-1 trading plan.
2 min read
